Sadahiro Naka, Kazuhiro Ooe, Yoshifumi Shirakami, Kenta Kurimoto, Toshihiro Sakai, Kazuhiro Takahashi, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, Hiroki Kato, et al. Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial. EJNMMI radiopharmacy and chemistry. 2024. 9. 1. 29-29
Mitsuaki Tatsumi, Fumihiko Soeda, Sadahiro Naka, Kenta Kurimoto, Kazuhiro Ooe, Hideyuki Fukui, Daisuke Katayama, Tadashi Watabe, Hiroki Kato, Noriyuki Tomiyama. Advantages of FBPA PET in evaluating early response of anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice: Comparison to FDG PET. Frontiers in Oncology. 2022. 12
Sadahiro Naka, Tadashi Watabe, Thomas Lindner, Jens Cardinale, Kenta Kurimoto, Melissa Moore, Mitsuaki Tatsumi, Yuriko Mori, Eku Shimosegawa, Frank Valla, et al. One-pot and one-step automated radio-synthesis of [18F]AlF-FAPI-74 using a multi purpose synthesizer: a proof-of-concept experiment. EJNMMI Radiopharmacy and Chemistry. 2021. 6. 1
Tadashi Watabe, Kazuko Kaneda-Nakashima, Kazuhiro Ooe, Yuwei Liu, Kenta Kurimoto, Takashi Murai, Yuka Shidahara, Kenji Okuma, Masanori Takeuchi, Masayuki Nishide, et al. Extended single-dose toxicity study of [211At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer. Annals of nuclear medicine. 2021. 35. 6. 702-718
Sadahiro Naka, Tadashi Watabe, Kenta Kurimoto, Motohide Uemura, Fumihiko Soeda, Oliver C Neels, Klaus Kopka, Mitsuaki Tatsumi, Hiroki Kato, Norio Nonomura, et al. Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination. EJNMMI radiopharmacy and chemistry. 2020. 5. 1. 18-18